Engineered Long-Acting PYY Analog Plus GLP-1 Drug Mimics Bariatric Surgery's Hormonal Effects
Peptide engineering created a PYY analog with 14+ hour half-life that, combined with a GLP-1 agonist, produced excellent weight loss and glucose control in obese mice.
Quick Facts
What This Study Found
The native PYY peptide has a very short half-life, making it impractical as a medication. Using combined peptide stapling and PEG-fatty acid conjugation, the researchers created potent PYY analogs that activate the NPY2 receptor and have rat half-lives exceeding 14 hours.
The 14-hour rat half-life is expected to translate to a human half-life suitable for once-weekly dosing, which would be practical for patients.
The lead candidate (compound 22) combined with a long-acting GLP-1 analog showed excellent efficacy in a diet-induced obesity mouse model for three key outcomes: glucose control, food intake reduction, and body weight loss. This combination approach mimics the hormonal changes seen after bariatric surgery.
Key Numbers
>14h rat half-life; compound 22 + GLP-1 analog; excellent glucose/food intake/weight loss outcomes in DIO mice
How They Did This
Researchers used peptide stapling and PEG-fatty acid conjugation to engineer PYY analogs. They measured NPY2R potency, pharmacokinetics in rats, and in vivo efficacy in diet-induced obesity mice. The lead compound was tested alone and in combination with a long-acting GLP-1 analog.
Why This Research Matters
Bariatric surgery increases both GLP-1 and PYY, which likely contributes to its exceptional weight loss results. Recreating this hormonal combination pharmacologically could give patients surgery-level benefits without the risks of an operation.
The engineering approach (stapling + PEG-fatty acid) is a significant technical achievement that solved PYY's short half-life problem.
The Bigger Picture
Bariatric surgery increases both GLP-1 and PYY, which likely drives its exceptional results. This engineered PYY analog could recreate the PYY component pharmacologically. Combined with existing GLP-1 drugs, it could provide surgery-level weight loss without the operating room.
What This Study Doesn't Tell Us
This was a mouse study. The predicted human half-life for once-weekly dosing needs to be confirmed in human pharmacokinetic studies.
Long-term efficacy and safety of PYY/GLP-1 combination therapy have not been assessed. The nausea and GI side effects common with gut hormone drugs were not specifically evaluated.
Questions This Raises
- ?Will the predicted once-weekly human dosing be confirmed in clinical pharmacokinetic studies?
- ?Does the PYY/GLP-1 combination produce more nausea than GLP-1 alone?
- ?Could triple combinations (PYY + GLP-1 + glucagon agonist) further improve outcomes?
Trust & Context
- Key Stat:
- >14h half-life engineered PYY analog predicting once-weekly human dosing, combined with GLP-1 for surgery-mimicking multi-hormone obesity treatment
- Evidence Grade:
- Moderate evidence from pharmacokinetic and mouse efficacy studies. Strong peptide engineering but human data needed.
- Study Age:
- Published in 2020. Multi-hormone obesity drug development has accelerated, with tirzepatide (dual GIP/GLP-1) approved since.
- Original Title:
- Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.
- Published In:
- Journal of medicinal chemistry, 63(17), 9660-9671 (2020)
- Authors:
- Lear, Sam(2), Pflimlin, Elsa, Zhou, Zhihong(2), Huang, David, Weng, Sharon, Nguyen-Tran, Van, Joseph, Sean B, Roller, Shane, Peterson, Scott, Li, Jing, Tremblay, Matthew, Schultz, Peter G, Shen, Weijun
- Database ID:
- RPEP-04928
Evidence Hierarchy
Frequently Asked Questions
Why combine PYY with GLP-1 drugs?
Bariatric surgery increases both PYY and GLP-1 naturally, and this combination likely drives its exceptional weight loss results. Adding a PYY drug to existing GLP-1 therapy could bring surgery-level results without surgery.
How was the short half-life problem solved?
Peptide stapling locked the molecule into a stable shape, and PEG-fatty acid conjugation made it bind to blood proteins for slow release. Together, these modifications extended the half-life from minutes to over 14 hours.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04928APA
Lear, Sam; Pflimlin, Elsa; Zhou, Zhihong; Huang, David; Weng, Sharon; Nguyen-Tran, Van; Joseph, Sean B; Roller, Shane; Peterson, Scott; Li, Jing; Tremblay, Matthew; Schultz, Peter G; Shen, Weijun. (2020). Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.. Journal of medicinal chemistry, 63(17), 9660-9671. https://doi.org/10.1021/acs.jmedchem.0c00740
MLA
Lear, Sam, et al. "Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.." Journal of medicinal chemistry, 2020. https://doi.org/10.1021/acs.jmedchem.0c00740
RethinkPeptides
RethinkPeptides Research Database. "Engineering of a Potent, Long-Acting NPY2R Agonist for Combi..." RPEP-04928. Retrieved from https://rethinkpeptides.com/research/lear-2020-engineering-of-a-potent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.